Antitrust Violation
Price-fixing conspiracy among major pharmaceutical distributors
Case Overview
A landmark competition law case alleging coordinated price-fixing among three major pharmaceutical wholesale distributors controlling 78% of the UK generic drug market. Evidence includes encrypted communications, parallel pricing patterns, and whistleblower testimony from former distribution manager.
Between 2019-2023, generic drug prices increased 340% across 47 essential medications despite stable manufacturing costs. Competition and Markets Authority (CMA) dawn raids in March 2023 uncovered communications between senior executives discussing "market stabilization" and "coordinated pricing strategies." NHS England estimates £890M in excess costs during the conspiracy period.
Legal Basis
Violation of Competition Act 1998 Chapter I prohibition (anti-competitive agreements) and Article 101 TFEU. Claims include follow-on damages under Section 47A for NHS trusts and private pharmacies. Strong precedent from CMA's successful prosecution of similar pharma cartel in 2021.
Expected Outcome
Settlement negotiations likely in £15-25M range given CMA's 85% success rate in cartel prosecutions and defendants' desire to avoid criminal referrals. Court has granted expedited disclosure given public interest. NHS England as intervenor strengthens damages claim.
Key Success Factors
Timeline Breakdown
Risk Assessment
CMA investigation uncovered direct evidence of coordination
Expert econometric analysis shows statistically impossible pricing patterns
Former distribution executive providing insider testimony under immunity
Coordinating settlement among three defendants may extend timeline
Legal Team
Experienced attorneys with proven track records in complex litigation
Sir Geoffrey Mitchell QC
Lead Counsel
Specialization
Cartel Prosecution & Damages
Background
Former CMA Senior Director with unparalleled expertise in pharmaceutical antitrust. Led successful prosecution of €1.4B vitamins cartel. Acted for claimants in landmark Trucks Cartel litigation recovering £84M. Appointed Queen's Counsel in 2018.
Dr. Rachel Winters
Economic Expert
Specialization
Pharmaceutical Market Analysis
Background
PhD Economics (Oxford), former Chief Economist at Office of Fair Trading. Testified in 25+ cartel cases with 90% success rate. Published extensively on pharmaceutical pricing and competition. Expert witness in CMA's precedent-setting drug cartel case.
Related Investment Opportunities
Similar cases you might be interested in
Ready to Invest in This Case?
Contact our investment team to discuss this opportunity and complete your due diligence.